Tocilizumab, an investigational agent for the treatment of moderate-to-severe rheumatoid arthritis, is a humanized anti-IL-6 receptor monoclonal antibody. Because tocilizumab contains a mouse monoclonal antibody grafted onto human immunoglobulin, the grafted antibody is less antigenic and has a longer half-life than the mouse antibody. When administered, tocilizumab inhibits IL-6 activity by competing for both the membrane-bound and soluble types of IL-6 receptors, thus eliminating IL-6 transduction into the cell.
Safety surveillance to transform drug development and oversight
August 1, 2008 FDA has launched the Sentinel Initiative to expand and improve medical product risk detection and evaluation. Instead of relying on passive, voluntary adverse event (AE) reports sent to FDA by physicians and pharmacists, the agency would be able to detect safety signals much more quickly through links to health information databases containing information about millions of patients.
Formulary archives are now available on ModernMedicine.com, a new online resource designed to meet the evolving needs of physicians. Register now (it's free and quick) or Find out more.
Keep visiting FormularyJournal.com for fresh content, news, opinions, editor's blogs and more.
Formulary archives are now available on ModernMedicine.com, a new online resource designed to meet the evolving needs of physicians.